Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy

Amit Kumar Rajora*, Divyashree Ravishankar, Hongbo Zhang, Jessica M Rosenholm*

*Corresponding author for this work

Research output: Contribution to journalReview Article or Literature Reviewpeer-review

25 Citations (Scopus)


Traditional chemotherapy, along with antiangiogenesis drugs (combination cancer therapy), has shown reduced tumor recurrence and improved antitumor effects, as tumor growth and metastasis are often dependent on tumor vascularization. However, the effect of combination chemotherapy, including synergism and additive and even antagonism effects, depends on drug combinations in an optimized ratio. Hence, nanoformulations are ideal, demonstrating a great potential for the combination therapy of chemo-antiangiogenesis for cancer. The rationale for designing various nanocarriers for combination therapy is derived from organic (polymer, lipid), inorganic, or hybrid materials. In particular, hybrid nanocarriers that consist of more than one material construct provide flexibility for different modes of entrapment within the same carrier—eg, physical adsorption, encapsulation, and chemical conjugation strategies. These multifunctional nanocarriers can thus be used to co-deliver chemo-and antiangiogenesis drugs with tunable drug release at target sites. Hence, this review attempts to survey the most recent advances in nanoformulations and their impact on cancer treatment in a combined regimen—ie, conventional cytotoxic and antiangiogenesis agents. The mechanisms and site-specific co-delivery strategies are also discussed herein, along with future prospects.
Original languageEnglish
Article number592
Issue number6
Publication statusPublished - 25 Jun 2020
MoE publication typeA2 Review article in a scientific journal


  • anticancer
  • antiangiogenic agents
  • nanoformulations
  • combination cancer therapy


Dive into the research topics of 'Recent Advances and Impact of Chemotherapeutic and Antiangiogenic Nanoformulations for Combination Cancer Therapy'. Together they form a unique fingerprint.

Cite this